1. Home
  2. ENTX vs MYPS Comparison

ENTX vs MYPS Comparison

Compare ENTX & MYPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ENTX

Entera Bio Ltd.

HOLD

Current Price

$1.18

Market Cap

62.6M

Sector

Health Care

ML Signal

HOLD

Logo PLAYSTUDIOS Inc.

MYPS

PLAYSTUDIOS Inc.

HOLD

Current Price

$0.41

Market Cap

55.5M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENTX
MYPS
Founded
2010
2011
Country
Israel
United States
Employees
N/A
543
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
62.6M
55.5M
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
ENTX
MYPS
Price
$1.18
$0.41
Analyst Decision
Strong Buy
Buy
Analyst Count
1
2
Target Price
$9.00
$3.00
AVG Volume (30 Days)
135.1K
349.3K
Earning Date
05-14-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.25
N/A
Revenue
$42,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$4.48
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.91
$0.41
52 Week High
$3.22
$1.68

Technical Indicators

Market Signals
Indicator
ENTX
MYPS
Relative Strength Index (RSI) 49.10 36.16
Support Level $1.17 N/A
Resistance Level $1.38 $0.49
Average True Range (ATR) 0.10 0.03
MACD 0.00 -0.00
Stochastic Oscillator 30.77 6.11

Price Performance

Historical Comparison
ENTX
MYPS

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.

About MYPS PLAYSTUDIOS Inc.

PLAYSTUDIOS Inc is engaged in gaming and related business. The Company develops and operates online and mobile social gaming applications (games or game), many of which incorporate a loyalty program offering real world rewards provided by a collection of awards partners. The Companies games are free-to-play and available via the Apple App Store, Google Play Store, Amazon Appstore and Facebook (collectively, platforms or platform operators). The Company creates games based on its own original content as well as third-party licensed brands. The Company generates revenue through the in-game sales of virtual currency and through advertising. The company has one operating segment with one business activity, developing and monetizing social games.

Share on Social Networks: